KLRK1 and neoplasm: NKG2DL-targeting CAR-γδ T cells enhanced cytotoxicity against tumor cell lines, with Vγ9Vδ2 T cells modified by NKG2D RNA-based CAR showing notable therapeutic effects in mouse tumor models [141].